| Original language | English (US) |
|---|---|
| Pages (from-to) | 63-75 |
| Number of pages | 13 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 36 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2022 |
| Externally published | Yes |
Keywords
- Brain tumors
- Gliomas
- Innovation
- Multidisciplinary approach
- Neurosurgery
ASJC Scopus subject areas
- Hematology
- Oncology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Hematology/Oncology Clinics of North America, Vol. 36, No. 1, 02.2022, p. 63-75.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - The Evolving Role of Neurosurgical Intervention for Central Nervous System Tumors
AU - Peruzzi, Pierpaolo
AU - Valdes, Pablo Q.
AU - Aghi, Manish K.
AU - Berger, Mitchel
AU - Chiocca, Ennio Antonio
AU - Golby, Alexandra J.
N1 - Funding Information: P. Peruzzi has received research support from NIH , Neurosurgery Research and Education Foundation , and The Sontag Foundation . He is named inventor on patents related to noncoding RNA technology. E.A. Chiocca is currently an advisor to Advantagene Inc., Alcyone Biosciences, Insightec, Inc., DNAtrix Inc, Immunomic Therapeutics, Seneca Therapeutics, GSK, and Voyager Therapeutics and has equity interest in DNAtrix, Immunomic Therapeutics, and Seneca Therapeutics; he has also advised Oncorus, Merck, Tocagen, Ziopharm, Stemgen, NanoTx., Ziopharm Oncology, Cerebral Therapeutics, Genenta. Merck, Janssen, Karcinolysis, Shanghai Biotech, and Sangamo Therapeutics. He has received research support from NIH, US Department of Defense , American Brain Tumor Association , National Brain Tumor Society , Alliance for Cancer Gene Therapy , Neurosurgical Research Education Foundation, Advantagene , NewLink Genetics , and Amgen . He also is a named inventor on patents related to oncolytic HSV1 and noncoding RNAs. Funding Information: P. Peruzzi has received research support from NIH, Neurosurgery Research and Education Foundation, and The Sontag Foundation. He is named inventor on patents related to noncoding RNA technology. E.A. Chiocca is currently an advisor to Advantagene Inc. Alcyone Biosciences, Insightec, Inc. DNAtrix Inc, Immunomic Therapeutics, Seneca Therapeutics, GSK, and Voyager Therapeutics and has equity interest in DNAtrix, Immunomic Therapeutics, and Seneca Therapeutics; he has also advised Oncorus, Merck, Tocagen, Ziopharm, Stemgen, NanoTx. Ziopharm Oncology, Cerebral Therapeutics, Genenta. Merck, Janssen, Karcinolysis, Shanghai Biotech, and Sangamo Therapeutics. He has received research support from NIH, US Department of Defense, American Brain Tumor Association, National Brain Tumor Society, Alliance for Cancer Gene Therapy, Neurosurgical Research Education Foundation, Advantagene, NewLink Genetics, and Amgen. He also is a named inventor on patents related to oncolytic HSV1 and noncoding RNAs.
PY - 2022/2
Y1 - 2022/2
KW - Brain tumors
KW - Gliomas
KW - Innovation
KW - Multidisciplinary approach
KW - Neurosurgery
UR - http://www.scopus.com/inward/record.url?scp=85115817903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115817903&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2021.08.003
DO - 10.1016/j.hoc.2021.08.003
M3 - Review article
C2 - 34565649
AN - SCOPUS:85115817903
SN - 0889-8588
VL - 36
SP - 63
EP - 75
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 1
ER -